Immunosuppressants for Sarcoidosis — Real-World Safety Data

Patients requiring treatment for sarcoidosis are usually started on systemic steroids and then transitioned to second- or third-line immunosuppression. The specific choice of medication is usually guided by efficacy and tolerance, as the safety profiles of these medications are not well studied in patients with sarcoidosis. To address this gap, researchers reviewed electronic health record data from nearly 14,000 patients with sarcoidosis who were receiving methotrexate, mycophenolate mofetil (MMF), azathioprine, leflunomide, or a tumor necrosis factor (TNF) inhibitor (infliximab or adalimumab).